130 related articles for article (PubMed ID: 20359660)
1. Cetuximab in metastatic colorectal cancer.
Wolf I; Golan T; Shani A; Aderka D
Lancet Oncol; 2010 Apr; 11(4):313-4; author reply 314. PubMed ID: 20359660
[No Abstract] [Full Text] [Related]
2. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
Garassino MC; Farina G; Rossi A; Martelli O; Torri V
J Clin Oncol; 2008 May; 26(15):2600; author reply 2601-2. PubMed ID: 18487581
[No Abstract] [Full Text] [Related]
3. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic colon cancer: "the times they are A-changing".
Kemeny NE
J Clin Oncol; 2013 Jun; 31(16):1913-6. PubMed ID: 23630214
[No Abstract] [Full Text] [Related]
5. [Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].
Nozawa K; Watanabe T
Gan To Kagaku Ryoho; 2010 May; 37(5):791-4. PubMed ID: 20495308
[TBL] [Abstract][Full Text] [Related]
6. [Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials].
Ariyama H; Kusaba H; Baba E
Gan To Kagaku Ryoho; 2010 May; 37(5):782-6. PubMed ID: 20495306
[TBL] [Abstract][Full Text] [Related]
7. KRAS status predicts response to cetuximab for metastatic colorectal cancer.
McBride D
ONS Connect; 2008 Aug; 23(8):25. PubMed ID: 18767573
[No Abstract] [Full Text] [Related]
8. Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
Cremolini C; Loupakis F; Ruzzo A; Perrone G; Rulli E; Vincenzi B; Tonini G; Graziano F; Muda AO; Falcone A
J Clin Oncol; 2010 Apr; 28(11):e173-4; author reply e175-6. PubMed ID: 20177018
[No Abstract] [Full Text] [Related]
9. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
[No Abstract] [Full Text] [Related]
10. [Biology applied to cancer treatments: the example of colorectal cancer].
Lièvre A; Laurent-Puig P
Rev Prat; 2010 Oct; 60(8):1100-2. PubMed ID: 21197742
[No Abstract] [Full Text] [Related]
11. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
[TBL] [Abstract][Full Text] [Related]
12. [Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].
Yoda Y; Yoshino T; Kadowaki S; Bando H; Okano S; Fukushima H; Fuse N; Tahara M; Doi T; Ohtsu A
Gan To Kagaku Ryoho; 2009 Jun; 36(6):1003-6. PubMed ID: 19542725
[TBL] [Abstract][Full Text] [Related]
13. Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy.
Mancuso A; Sollami R; Recine F; Cerbone L; Macciomei MC; Leone A
J Clin Oncol; 2010 Dec; 28(36):e756-8. PubMed ID: 20855834
[No Abstract] [Full Text] [Related]
14. Cetuximab in the first-line therapy of metastatic colorectal carcinoma: not so CRYSTAL clear.
Windsor AC; Cohen R; Jiao LR; Stebbing J
Future Oncol; 2008 Dec; 4(6):741-4. PubMed ID: 19086837
[No Abstract] [Full Text] [Related]
15. KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer.
Jimeno A; Messersmith WA; Hirsch FR; Franklin WA; Eckhardt SG
Cancer J; 2009; 15(2):110-3. PubMed ID: 19390304
[TBL] [Abstract][Full Text] [Related]
16. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.
Lenz HJ; Chu E; Grothey A
Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-13, 14-6. PubMed ID: 19378369
[TBL] [Abstract][Full Text] [Related]
18. Challenges and opportunities for use of cost-effectiveness analysis.
Yabroff KR; Schrag D
J Natl Cancer Inst; 2009 Sep; 101(17):1161-3. PubMed ID: 19666852
[No Abstract] [Full Text] [Related]
19. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
Malik Z; Eng C
Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
[No Abstract] [Full Text] [Related]
20. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
